Source disclosure: February 12, 2026
TRANSGENIC GROUP INC. [2342.T]
TOKYO, Feb 12 (Pulse News Wire) – Transgenic Group Inc. (2342.T) announced today that it received approval from the Tokyo Stock Exchange to transition its listing from the Growth Market to the Standard Market effective February 19, 2026.
The company had previously applied for the change in October 2024 but withdrew the application due to delays in disclosing interim reports caused by misconduct discovered among some employees of a subsidiary. After implementing necessary measures and reapplying in January 2026, the company secured the approval. Additionally, Transgenic Group decided to withdraw its plan submitted on December 26, 2024, aimed at meeting the maintenance standards of the Growth Market, following the approval for the market classification change. Since its inception, Transgenic Group has focused on expanding its pharmaceutical support services through M&A activities and initiating investment consulting businesses.
As a result, the company's consolidated revenue increased from approximately ¥2.200 billion in March 2017 to approximately ¥13.00 billion in March 2025. The number of consolidated subsidiaries also grew from four at the end of March 2017 to sixteen at the end of March 2025. In April 2021, the group shifted to a pure holding company structure to align with its diversified operations and enhance governance. With this restructuring, Transgenic Group aims to achieve sustainable growth and improve long-term corporate value while continuing its current initiatives.
AI-translated content. 🟢 Confidence: High See terms • Original filing